Can a cancer drug slow ALS? a trial aims to find out

NCT ID NCT04744532

Completed Disease control Sponsor: Kyoto University Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study tests whether bosutinib, a drug currently used for certain cancers, can help people with amyotrophic lateral sclerosis (ALS), a progressive nerve disease. The trial has two parts: the first finds a safe dose, and the second checks if that dose slows the decline in daily function over 24 weeks. Participants take bosutinib by mouth once daily. The goal is to see if this drug can slow the disease's progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bosutinib
What this could lead to: If bosutinib slows ALS progression, it could offer a new treatment option for this devastating disease.
What could go wrong: This is an early-phase trial, so the drug may not work or may cause side effects. The results are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Hiroshima University

Hiroshima, Japan
Kitasato University

Sagamihara, Japan
Kyoto University

Kyoto, Japan
Nara Medical University

Kashihara, Japan
Toho University

Tokyo, Japan
Tokushima university

Tokushima, Japan
Tottori University

Yonago, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.